Evidence map›Paper›PMID 40206841›Full record

ArticleIJID regions2025

Raman Swathy Vaman, George Dilu Thomas, Madhanraj Kalyanasundaram, Surabhi Soman, Mathew J Valamparampil, Rakesh Puroshothama Bhat Susheela, Manoj V Murhekar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Raman Swathy VamanDistrict Hospital, Kanhangad, India.
George Dilu ThomasMOSC Medical College, Kolenchery, India.
Madhanraj KalyanasundaramICMR-NIE, Chennai, India.
Surabhi SomanKerala State Health Services, Thiruvananthapuram, India.
Mathew J ValamparampilKerala State Health Services, Thiruvananthapuram, India.
Rakesh Puroshothama Bhat SusheelaThe Union Southeast Asia Office, New Delhi, India.
Manoj V MurhekarICMR-NIE, Chennai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: We conducted a study to estimate the incidence of adverse drug reactions (ADRs) in the drug-resistant tuberculosis (DR-TB) cohort in Kerala in 2020 and describe the characteristics of the reported ADRs. Methods: A non-concurrent cohort study was conducted among all patients with DR-TB across 14 districts in Kerala from January 1, 2020 to December 31, 2020. We collected data on ADRs from patients, "Nikshay" web-portal, treatment cards, case sheets, and registers. We described ADRs by organ system, causality, severity, preventability, predictability, and seriousness of the reaction using standard tools. Results: Of the 364 persons initiated on treatment, 304 (83.5%) had at least one of the 28 listed adverse reactions, with an incidence of 27.6 ADR per 100 person-months of treatment. Gastrointestinal disorders had the highest incidence 365 per 1046 (35%). A total of 1001 of 1046 (95.7%) ADRs were non-predictable, and 405 of 1046 (39%) were definitely preventable. A total of 83 of 304 (27.3%) patients had severe ADR, and 56 of 304 (18.4%) had serious ADR. A total of 87 of 304 (28.6%) patients with ADR required interruption of the probable offending drug, with 64 of 87 (73.6%) temporary and 23 of 87 (26.4%) permanent interruptions. Conclusions: Four-fifths of all patients on therapy had at least one of the 28 listed adverse reaction and one-fifth had serious ADR. ADRs can lead to treatment interruptions. Early detection and prompt management is essential for improving treatment outcomes in patients with DR-TB.

Indexed as

Adverse drug reactionsExtensively drug-resistant tuberculosisIndiaMulti-drug–resistant tuberculosisTreatment outcomes

Identifiers

PMID40206841
PMCPMC11979944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.